Equities

PhoenixBio Co Ltd

6190:TYO

PhoenixBio Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)460.00
  • Today's Change0.00 / 0.00%
  • Shares traded9.70k
  • 1 Year change-18.29%
  • Beta0.7418
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1,3851,5551,326
Total Receivables, Net217287226
Total Inventory451365258
Prepaid expenses------
Other current assets, total798544
Total current assets2,1322,2921,854
Property, plant & equipment, net543539410
Goodwill, net------
Intangibles, net115.231.51
Long term investments9.49125--
Note receivable - long term------
Other long term assets4.662011
Total assets2,7153,0192,280
LIABILITIES
Accounts payable134037
Accrued expenses7.754.46--
Notes payable/short-term debt10000
Current portion long-term debt/capital leases13391531
Other current liabilities, total168326371
Total current liabilities4211,286439
Total long term debt4912151,008
Total debt7241,1301,039
Deferred income tax1.56----
Minority interest------
Other liabilities, total3.343.345.62
Total liabilities9181,5041,452
SHAREHOLDERS EQUITY
Common stock2,5632,4542,364
Additional paid-in capital783674584
Retained earnings (accumulated deficit)(1569)(1599)(2099)
Treasury stock - common(0.04)(0.04)(0.04)
Unrealized gain (loss)--(11)--
Other equity, total22(3.58)(20)
Total equity1,7981,514828
Total liabilities & shareholders' equity2,7153,0192,280
Total common shares outstanding4.033.633.31
Treasury shares - common primary issue0.000.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.